Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

BridgeBio Pharma (BBIO) Profit After Tax (2019 - 2025)

BridgeBio Pharma's Profit After Tax history spans 7 years, with the latest figure at -$194.6 million for Q4 2025.

  • For Q4 2025, Profit After Tax rose 27.21% year-over-year to -$194.6 million; the TTM value through Dec 2025 reached -$732.9 million, down 34.89%, while the annual FY2025 figure was -$732.9 million, 34.89% down from the prior year.
  • Profit After Tax for Q4 2025 was -$194.6 million at BridgeBio Pharma, down from -$184.9 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$2.6 million in Q2 2022 and bottomed at -$267.4 million in Q4 2024.
  • The 5-year median for Profit After Tax is -$162.6 million (2021), against an average of -$150.0 million.
  • The largest annual shift saw Profit After Tax soared 97.49% in 2022 before it crashed 6179.91% in 2023.
  • A 5-year view of Profit After Tax shows it stood at -$152.3 million in 2021, then increased by 7.69% to -$140.6 million in 2022, then decreased by 21.17% to -$170.3 million in 2023, then crashed by 56.98% to -$267.4 million in 2024, then grew by 27.21% to -$194.6 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Profit After Tax are -$194.6 million (Q4 2025), -$184.9 million (Q3 2025), and -$183.8 million (Q2 2025).